(Q39165575)

9 September 2017

Pirfenidone for the treatment of idiopathic pulmonary fibrosis (English)

1 reference

9 September 2017

1 reference

Peter M George

1

1 reference

PubMed ID

28266906

9 September 2017

Athol U Wells

series ordinal

2

1 reference

PubMed ID

28266906

9 September 2017

language of work or name

English

0 references

publication date

7 March 2017

1 reference

Expert Review of Clinical Pharmacology

9 September 2017

1 reference

9 September 2017

10

1 reference

9 September 2017

5

1 reference

9 September 2017

483-491

1 reference

An official American Thoracic Society/European Respiratory Society statement: Update of the international multidisciplinary classification of the idiopathic interstitial pneumonias

9 September 2017

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2017.1295846

Idiopathic pulmonary fibrosis in US Medicare beneficiaries aged 65 years and older: incidence, prevalence, and survival, 2001-11.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2017.1295846

Incidence and mortality of idiopathic pulmonary fibrosis and sarcoidosis in the UK

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2017.1295846

Prognostic significance of histopathologic subsets in idiopathic pulmonary fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2017.1295846

The prognostic significance of the histologic pattern of interstitial pneumonia in patients presenting with the clinical entity of cryptogenic fibrosing alveolitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2017.1295846

An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2017.1295846

Idiopathic pulmonary fibrosis: Recent advances on pharmacological therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2017.1295846

Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2017.1295846

Lung fibrosis is ameliorated by pirfenidone fed in diet after the second dose in a three-dose bleomycin-hamster model

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2017.1295846

Idiopathic pulmonary fibrosis: multiple causes and multiple mechanisms?

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2017.1295846

A novel anti-fibrotic agent pirfenidone suppresses tumor necrosis factor-alpha at the translational level

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2017.1295846

Inhibition of experimental acute pulmonary inflammation by pirfenidone

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2017.1295846

Pirfenidone inhibits T-cell activation, proliferation, cytokine and chemokine production, and host alloresponses

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2017.1295846

Pirfenidone suppresses tumor necrosis factor-alpha, enhances interleukin-10 and protects mice from endotoxic shock

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2017.1295846

Antifibrotic action of pirfenidone and prednisolone: different effects on pulmonary cytokines and growth factors in bleomycin-induced murine pulmonary fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2017.1295846

Anti-inflammatory effect of pirfenidone in the bleomycin-hamster model of lung inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2017.1295846

Pirfenidone induces intercellular adhesion molecule-1 (ICAM-1) down-regulation on cultured human synovial fibroblasts

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2017.1295846

Effect of pirfenidone on proliferation, TGF-β-induced myofibroblast differentiation and fibrogenic activity of primary human lung fibroblasts.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2017.1295846

Pirfenidone: a novel pharmacological agent that inhibits leiomyoma cell proliferation and collagen production

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2017.1295846

Pirfenidone reduces fibronectin synthesis by cultured human retinal pigment epithelial cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2017.1295846

The impact of TGF-β on lung fibrosis: from targeting to biomarkers

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2017.1295846

Transforming growth factor-beta (TGF-beta) in silicosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2017.1295846

Expression of transforming growth factor beta (TGF-beta1) in human epithelial alveolar cells: a pro-inflammatory mediator independent pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2017.1295846

Mouse and human lung fibroblasts regulate dendritic cell trafficking, airway inflammation, and fibrosis through integrin αvβ8-mediated activation of TGF-β.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2017.1295846

Differential effects of pirfenidone on acute pulmonary injury and ensuing fibrosis in the hamster model of amiodarone-induced pulmonary toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2017.1295846

Cyclooxygenase-2 deficiency results in a loss of the anti-proliferative response to transforming growth factor-beta in human fibrotic lung fibroblasts and promotes bleomycin-induced pulmonary fibrosis in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2017.1295846

Possible involvement of pirfenidone metabolites in the antifibrotic action of a therapy for idiopathic pulmonary fibrosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2017.1295846

Pirfenidone inhibits TGF-β1-induced over-expression of collagen type I and heat shock protein 47 in A549 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2017.1295846

Pirfenidone inhibits obliterative airway disease in mouse tracheal allografts

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2017.1295846

Pirfenidone attenuates expression of HSP47 in murine bleomycin-induced pulmonary fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2017.1295846

Pirfenidone inhibits NADPH-dependent microsomal lipid peroxidation and scavenges hydroxyl radicals

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2017.1295846

Effect of pirfenidone on rat hepatic stellate cell proliferation and collagen production

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2017.1295846

Pirfenidone effectively reverses experimental liver fibrosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2017.1295846

Potential approaches to reverse or repair renal fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2017.1295846

Pirfenidone is renoprotective in diabetic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2017.1295846

Pirfenidone mitigates left ventricular fibrosis and dysfunction after myocardial infarction and reduces arrhythmias

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2017.1295846

Antifibrotic activities of pirfenidone in animal models

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2017.1295846

Pirfenidone attenuates cardiac fibrosis in a mouse model of TAC-induced left ventricular remodeling by suppressing NLRP3 inflammasome formation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2017.1295846

Getting to the heart of the matter: new insights into cardiac fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2017.1295846

Pirfenidone exhibits cardioprotective effects by regulating myocardial fibrosis and vascular permeability in pressure-overloaded hearts.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2017.1295846

Effect of food and antacids on the pharmacokinetics of pirfenidone in older healthy adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2017.1295846

Pharmacokinetic evaluation of tissue distribution of pirfenidone and its metabolites for idiopathic pulmonary fibrosis therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2017.1295846

Single- and multiple-dose pharmacokinetics of pirfenidone, an antifibrotic agent, in healthy Chinese volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2017.1295846

Double-blind, placebo-controlled trial of pirfenidone in patients with idiopathic pulmonary fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2017.1295846

Pirfenidone in idiopathic pulmonary fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2017.1295846

Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2017.1295846

A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2017.1295846

A new era in idiopathic pulmonary fibrosis: considerations for future clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2017.1295846

Idiopathic pulmonary fibrosis: clinically meaningful primary endpoints in phase 3 clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2017.1295846

A progression-free end-point for idiopathic pulmonary fibrosis trials: lessons from cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2017.1295846

The win ratio: a new approach to the analysis of composite endpoints in clinical trials based on clinical priorities

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2017.1295846

Effect of continued treatment with pirfenidone following clinically meaningful declines in forced vital capacity: analysis of data from three phase 3 trials in patients with idiopathic pulmonary fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2017.1295846

Pirfenidone for idiopathic pulmonary fibrosis: analysis of pooled data from three multinational phase 3 trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2017.1295846

Safety of pirfenidone in patients with idiopathic pulmonary fibrosis: integrated analysis of cumulative data from 5 clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2017.1295846

Pirfenidone in idiopathic pulmonary fibrosis: expert panel discussion on the management of drug-related adverse events

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2017.1295846

Long-term clinical and real-world experience with pirfenidone in the treatment of idiopathic pulmonary fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2017.1295846

Real world experiences: pirfenidone is well tolerated in patients with idiopathic pulmonary fibrosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2017.1295846

Pirfenidone in idiopathic pulmonary fibrosis: real-life experience from a German tertiary referral center for interstitial lung diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2017.1295846

Comprehensive assessment of the long-term safety of pirfenidone in patients with idiopathic pulmonary fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2017.1295846

Combination therapy: the future of management for idiopathic pulmonary fibrosis?

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2017.1295846

Hot of the breath: Mortality as a primary end-point in IPF treatment trials: the best is the enemy of the good

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2017.1295846

10.1080/17512433.2017.1295846

21 January 2018

Identifiers

DOI

1 reference

9 September 2017

1 reference

PubMed ID

28266906